产品编号 | 产品名称 | 产品包装 | 产品价格 |
SM6152-10mM | 黄芪甲苷(98%, HPLC) | 10mM×0.2ml | 90.00元 |
SM6152-25mg | 黄芪甲苷(98%, HPLC) | 25mg | 120.00元 |
SM6152-100mg | 黄芪甲苷(98%, HPLC) | 100mg | 408.00元 |
中文名 | 黄芪甲苷 |
英文名 | Astragaloside IV |
中文别名 | 黄芪甙;黄芪皂苷 IV |
英文别名 | Astrasieversianin XIV; Cyclosieversioside F; Cyclosiversioside F; Astramembrannin I; Astragaloside A |
来源 | 蒙古黄耆Astragalus mongholicus Bunge |
化合物类型 | 萜类(Terpenoids)>三萜>羊毛甾烷型四环三萜皂苷 |
化学式 | C41H68O14 |
分子量 | 784.97 |
CAS号 | 84687-43-4 |
纯度 | 98%, HPLC |
溶剂/溶解度 | DMSO: ≥ 100 mg/ml (127.39 mM) |
溶液配制 | 10mg加入1.27l DMSO,或者每7.85mg加入1ml DMSO,配制成10mM溶液。 |
产品描述 | Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. | ||||
信号通路 | - | ||||
靶点 | MMP-2 | MMP-9 | ERK1 | ERK2 | JNK |
IC50 | - | - | - | - | - |
体外研究 | Astragaloside IV (10, 20, 40 ng/ml) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/ml) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9. | ||||
体内研究 | Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD. | ||||
临床实验 | N/A |
1.Li M, et al. Neurosci Lett. 2017,639:114-119.
2.He CS, et al. Cell Physiol Biochem. 2016,40(5):1221-1229.
3.Liu L, et al. Zhonghua Gan Zang Bing Za Zhi. 2016,24(10):772-777.
4.Jiang K, et al. Int Immunopharmacol. 2016,42:195-20.
包装清单:产品编号 | 产品名称 | 包装 |
SM6152-10mM | 黄芪甲苷(98%, HPLC) | 10mM×0.2ml |
SM6152-25mg | 黄芪甲苷(98%, HPLC) | 25mg |
SM6152-100mg | 黄芪甲苷(98%, HPLC) | 100mg |
- | 说明书 | 1份 |
-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。